

Title (en)

MODULATED IMMUNODOMINANCE THERAPY

Title (de)

MODULIERTE IMMUNDOMINANZTHERAPIE

Title (fr)

THÉRAPIE D'IMMUNODOMINANCE MODULÉE

Publication

EP 2714072 A1 20140409 (EN)

Application

EP 12725589 A 20120525

Priority

- US 201161490505 P 20110526
- US 2012039605 W 20120525

Abstract (en)

[origin: WO2012162620A1] The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting. In effect, the transplantation exogenously generated T cells reactive to the subdominant antigens is recapitulating priming and rebalancing the patient's immune response to target previously subdominant antigens in the cells or organism to produce a therapeutic benefit.

IPC 8 full level

A61K 39/00 (2006.01); **A61K 39/245** (2006.01); **A61K 39/29** (2006.01)

CPC (source: EP KR US)

A61K 9/0019 (2013.01 - US); **A61K 9/0021** (2013.01 - US); **A61K 35/17** (2013.01 - KR US); **A61K 39/0008** (2013.01 - US);
A61K 39/0011 (2013.01 - US); **A61K 39/12** (2013.01 - EP KR US); **A61K 39/245** (2013.01 - KR US); **A61K 39/29** (2013.01 - KR);
A61K 39/292 (2013.01 - EP US); **A61K 39/4611** (2023.05 - EP KR); **A61K 39/4615** (2023.05 - EP); **A61K 39/4621** (2023.05 - EP KR);
A61K 39/4622 (2023.05 - EP KR); **A61K 39/46433** (2023.05 - EP); **A61K 39/46484** (2023.05 - EP); **A61K 39/46486** (2023.05 - EP);
A61K 39/46488 (2023.05 - EP); **A61K 39/46491** (2023.05 - EP); **A61K 39/464838** (2023.05 - EP); **A61P 29/00** (2018.01 - EP KR);
A61P 31/00 (2018.01 - KR); **A61P 35/00** (2018.01 - EP KR); **A61P 37/00** (2018.01 - EP); **A61P 37/02** (2018.01 - EP);
A61P 37/06 (2018.01 - EP KR); **C12N 5/06** (2013.01 - KR); **C12N 5/0617** (2013.01 - KR); **C12N 5/0636** (2013.01 - EP KR US);
C12N 7/00 (2013.01 - US); **A61K 2035/124** (2013.01 - US); **A61K 2039/5158** (2013.01 - US); **A61K 2039/53** (2013.01 - US);
A61K 2039/55566 (2013.01 - US); **A61K 2039/585** (2013.01 - US); **A61K 2239/31** (2023.05 - EP KR); **A61K 2239/38** (2023.05 - EP KR);
A61K 2239/46 (2023.05 - KR); **A61K 2239/48** (2023.05 - EP); **A61K 2239/53** (2023.05 - EP); **C12N 2501/2302** (2013.01 - EP US);
C12N 2501/2304 (2013.01 - US); **C12N 2501/2306** (2013.01 - US); **C12N 2501/2307** (2013.01 - EP US); **C12N 2501/2312** (2013.01 - US);
C12N 2501/2315 (2013.01 - US); **C12N 2501/2321** (2013.01 - US); **C12N 2501/999** (2013.01 - EP US); **C12N 2502/1121** (2013.01 - EP);
C12N 2502/1157 (2013.01 - EP); **C12N 2710/16011** (2013.01 - EP); **C12N 2710/16034** (2013.01 - US); **C12N 2710/16234** (2013.01 - US);
C12N 2730/10134 (2013.01 - EP US); **C12N 2730/10171** (2013.01 - US)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2012162620 A1 20121129; AU 2012258603 A1 20140116; AU 2017203671 A1 20170615; AU 2019201456 A1 20190321;
AU 2021200831 A1 20210304; CA 2874431 A1 20121129; CN 103906531 A 20140702; CN 111529697 A 20200814;
EP 2714072 A1 20140409; EP 4285922 A1 20231206; HK 1199404 A1 20150703; JP 2014516538 A 20140717; KR 20140068810 A 20140609;
KR 20160104753 A 20160905; RU 2013157923 A 20150710; SG 10201604236R A 20160728; SG 10202012534V A 20210128;
TW 201313902 A 20130401; TW 201934749 A 20190901; TW 202321442 A 20230601; TW I774957 B 20220821; US 11723921 B2 20230815;
US 2014099341 A1 20140410; US 2017042998 A1 20170216; US 2017042999 A1 20170216; US 2017043000 A1 20170216;
US 2017043001 A1 20170216; US 2017101625 A1 20170413; US 2017216357 A1 20170803; US 2024189353 A1 20240613

DOCDB simple family (application)

US 2012039605 W 20120525; AU 2012258603 A 20120525; AU 2017203671 A 20170531; AU 2019201456 A 20190301;
AU 2021200831 A 20210210; CA 2874431 A 20120525; CN 201280037470 A 20120525; CN 201911266293 A 20120525;
EP 12725589 A 20120525; EP 23158828 A 20120525; HK 14113011 A 20141229; JP 2014512143 A 20120525; KR 20137034616 A 20120525;
KR 20167023641 A 20120525; RU 2013157923 A 20120525; SG 10201604236R A 20120525; SG 10202012534V A 20120525;
TW 101118979 A 20120528; TW 108117367 A 20120528; TW 111127515 A 20120528; US 201214122036 A 20120525;
US 201615337415 A 20161028; US 201615337506 A 20161028; US 201615337556 A 20161028; US 201615337620 A 20161028;
US 201615337661 A 20161028; US 201715486864 A 20170413; US 202318343693 A 20230628